Randomised controlled trial of the treatment of hyperlipidaemia on progression of atherosclerosis.
Two types of end-point measurement are presently available in clinical trials of the effect of treatment of hyperlipidaemia on cardiovascular disease; these are the incidence of clinical events and the arteriographic assessment of progression or regression of atherosclerosis. These approaches are briefly reviewed. In the present trial, 25 hyperlipidaemic men with symptomatic femoral atherosclerosis underwent biplanar femoral arteriography at baseline. They were then randomised into treatment and usual-care groups; treatment was individualized, comprising a lipid-lowering diet with cholestyramine, nicotinic acid or clofibrate as appropriate for the lipoprotein disorder. Mean cholesterol and triglyceride levels were 19% and 37% lower in the treatment group. Arteriography was repeated after a mean period of 19 months. With attention to blinding of observers, changes in arteriograms were quantitated using computerised image analysis and visual methods, and expressed both by patient and by arterial segment. All end-points were in conformity and showed a lower rate of progression of arterial disease in the treatment group, and a higher frequency of segmental regression in treated patients. In this small trial of patients with functionally-significant atherosclerosis, effective treatment of hyperlipidaemia favourably affected the course of the arterial disease.
D000792:Angiography; D001161:Arteriosclerosis / Q000097:blood / Q000628:therapy*; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D006801:Humans; D006949:Hyperlipidemias / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011897:Random Allocation
D008078:Cholesterol, LDL